本文已被：浏览 553次 下载 326次
Received:April 16, 2025 Published Online:July 21, 2025
Received:April 16, 2025 Published Online:July 21, 2025
中文摘要: 近年来结直肠癌与糖尿病共病现象愈发普遍，已成为严重危害人类健康的公共卫生问题之一。高血糖状态、胰岛素抵抗及慢性炎症等糖尿病病理机制可促进结直肠癌进展。此外，胰岛素、二甲双胍、胰高血糖素样肽-1受体激动剂（GLP-1RA）和钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）等降糖药物对2型糖尿病（T2DM）合并结直肠癌患者的预后影响也存在争议。本文将从T2DM影响结直肠癌预后的分子机制及不同降糖药物对结直肠癌合并T2DM患者预后的影响进行综合分析。
中文关键词: 结直肠癌 2型糖尿病 胰岛素抵抗 胰高血糖素样肽⁃1受体激动剂 钠-葡萄糖共转运蛋白2抑制剂 预后
Abstract:In recent years，the comorbidity of CRC and DM has become more and more common，and has become one of the public health problems that seriously endanger human health. The pathological mechanisms of DM such as hyperglycemia，insulin resistance and chronic inflammation can promote the progression of CRC.In addition，the effects of hypoglycemic drugs such as insulin，metformin，glucagon-like peptide-1 receptor agonist and SGLT2ion the prognosis of patients with T2DM complicated with CRC are also controversial. This article will comprehensively analyze the molecular mechanism of T2DM affecting the prognosis of CRC and the effects of different hypoglycemic drugs on the prognosis of CRC patients with T2DM.
keywords: Colorectal cancer Type 2 diabetes Insulin resistance Glucagon-like peptide-1 receptor agonist SGLT2 inhibitor Prognosis
文章编号： 中图分类号：R735.3 文献标志码：A
基金项目:
| Author Name | Affiliation |
| ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li | Department of Oncology,the Second Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650000,China |
| Author Name | Affiliation |
| ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li | Department of Oncology,the Second Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650000,China |
引用文本：